XML 32 R20.htm IDEA: XBRL DOCUMENT v3.19.1

Revenues (Tables)

3 Months Ended

Mar. 31, 2019

Segment Reporting [Abstract]

Summary of net revenue

The Company’s net revenues consisted of the following for the three months ended March 31, 2019 and 2018:

			Three months ended March 31,
			2019						2018
Products:
Acetadote			$	849,502					$	1,273,764
Omeclamox-Pak			199,537						141,392
Kristalose			3,307,658						3,269,901
Vaprisol			286,676						93,890
Caldolor			1,317,074						1,039,747
Ethyol			3,091,991						2,256,073
Totect			80,896						412,774
Vibativ			2,060,195						—
Other			709,218						100,064
Total net revenues			$	11,902,747					$	8,587,605

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration